A carregar...
New advancements and developments in treatment of renal cell carcinoma: focus on pazopanib
With the recent approval of pazopanib, an oral multitargeted tyrosine kinase inhibitor which potently targets vascular endothelial growth factor receptors 1–3, platelet-derived growth factor, and c-kit, six agents are now available for use in the management of metastatic renal cell carcinoma (RCC)....
Na minha lista:
| Main Authors: | , , |
|---|---|
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Dove Medical Press
2010
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC2962303/ https://ncbi.nlm.nih.gov/pubmed/21049083 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|